The SHC3 antibody targets the SHC (Src homology 2 domain-containing transforming protein C3), a member of the SHC family of adaptor proteins involved in intracellular signaling. SHC proteins, including SHC1. SHC2. SHC3. and SHC4. regulate signal transduction pathways by linking activated receptor tyrosine kinases (RTKs) to downstream effectors like the Ras/MAPK cascade. SHC3. encoded by the *SHC3* gene (also called *NSHC*), is primarily expressed in the nervous system and plays a critical role in neurotrophin signaling, neuronal differentiation, and synaptic plasticity. Structurally, SHC3 contains a phosphotyrosine-binding (PTB) domain, a CH1 region with tyrosine phosphorylation sites, and a CH2 domain, enabling interactions with signaling molecules such as Trk receptors.
SHC3 is implicated in neurological disorders and cancer. In neuroblastoma and other cancers, SHC3 overexpression correlates with tumor progression, metastasis, and drug resistance, likely by enhancing RTK-mediated survival pathways. SHC3 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to investigate SHC3's role in signaling networks and its potential as a therapeutic target. Research on SHC3 antibodies also aids in understanding its tissue-specific signaling dynamics and crosstalk with other pathways, such as PI3K/AKT, in disease mechanisms.